The diagnosis and medical management of advanced neuroendocrine tumors.
The DOI matches its Crossref record; 657 of the 670 references it cites were found in a registry or an index.
Abstract
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that originate from endocrine glands such as the pituitary, the parathyroids, and the (neuroendocrine) adrenal, as well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells dispersed between exocrine cells, such as endocrine cells of the digestive (gastroenteropancreatic) and respiratory tracts. Conventionally, NETs may present with a wide variety of functional or nonfunctional endocrine syndromes and may be familial and have other associated tumors. Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance. Imaging modalities include endoscopic ultrasonography, computed tomography and magnetic resonance imaging, and particularly, scintigraphy with somatostatin analogs and metaiodobenzylguanidine. Successful treatment of disseminated NETs requires a multimodal approach; radical tumor surgery may be curative but is rarely possible. Well-differentiated and slow-growing gastroenteropancreatic tumors should be treated with somatostatin analogs or alpha-interferon, with chemotherapy being reserved for poorly differentiated and progressive tumors. Therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails. Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the combination of noninvasive and selected invasive modalities (particularly endoscopic ultrasound), most insulinomas are localized preoperatively (72, 78).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
In the citing paper
“Although the results with a given method reflect the experience and expertise with that method at a given center, computed tomography, MRI, and transabdominal ultrasonography detect most insulinomas (71-73).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
Citations
Cites
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
An analysis of 8305 cases of carcinoid tumors
Modlin, I. M., & Sandor, A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2 · Cited by 1,200
The Complex of Myxomas, Spotty Pigmentation, and Endocrine Overactivity
CARNEY, J. A., GORDON, H., CARPENTER, P. C., SHENOY, B. V., & W. GO, V. L. (1985) · Medicine · doi:10.1097/00005792-198507000-00007 · Cited by 1,114
Research works printed but not linked: 3
- Krenning, 1994, Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide., Semin Oncol, 21, 6
- Janson, 2000, Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors., J Nucl Med, 41, 1514
- Bartsch, 1990, Treatment of metastatic carcinoid tumors by recombinant human interferon-α. Results from a phase II study., J Cancer Res Clin Oncol, 116, 305
Cited by
Items 101–200 of 679
The management of neuroendocrine tumours: A nutritional viewpoint
Gallo, M., Muscogiuri, G., Pizza, G., Ruggeri, R. M., Barrea, L., Faggiano, A., Colao, A., & on behalf of NIKE Group (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1390729 · Cited by 64
“…times it occurs in non-functioning GEP NETs as a consequence of intestinal obstruction by the tumour mass or represents a side effect of medical therapies of either functioning or non-functioning NETs (SSAs, chemotherapy, everolimus, sunitinib) (Kaltsas et al. 2004; Modlin et al. 2008; Chung 2016).”
BackgroundInfluentialNasr, C. E., Mason, A., Mayberg, M. R., Staugaitis, S. M., & Asa, S. L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0610 · Cited by 62
“Well-differentiated NETs can secrete amines and peptides and cause clinical syndromes ( 10 ).”
BackgroundAnalysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography
Mörk, H., Ignee, A., Schuessler, G., Ott, M., & Dietrich, C. F. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520601021765 · Cited by 62
“The various cell types of the neuroendocrine cell system can secrete specific products peptides and biogenic amines such as serotonin, corticotropin (ACTH), histamine, dopamine, substance P, neurotensin, prostaglandins, kallikrein and tachykinins [13].”
BackgroundZitzmann, K., Brand, S., Toni, E. N. D., Baehs, S., Göke, B., Meinecke, J., Spöttl, G., Meyer, H. H. H. D., & Auernhammer, C. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2575 · Cited by 66
“The majority of neuroendocrine tumors have already metastasized at the time of diagnosis, resulting in a 5-year survival rate of less than 50% (1, 2).”
BackgroundOng, G. S. Y., Henley, D., Hurley, D. M., Turner, J. H., Claringbold, P. G., & Fegan, P. G. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1010 · Cited by 62
“abdominal pain, elevated transaminases) is the most common adverse event [7].”
BackgroundInfluentialImpact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours
Castaldi, P., Rufini, V., Treglia, G., Bruno, I., Perotti, G., Stifano, G., Barbaro, B., & Giordano, A. (2008) · La radiologia medica · doi:10.1007/s11547-008-0319-9 · Cited by 59
Grozinsky‐Glasberg, S., Benbassat, C. A., Tsvetov, G., Feinmesser, R., Peretz, H., Shimon, I., & Lapidot, M. (2007) · Thyroid · doi:10.1089/thy.2006.0229 · Cited by 59
“Elevated postoperative serum calcitonin levels were found to be a strong predictor of locoregional spread and distant metastases, as well as disease-specific survival (5,22,23,25,34).”
InfluentialJiménez, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00277 · Cited by 61
“For many years, interferon alpha-2b and octreotide analogs were considered the pillars of treatment for patients with gastroenteropancreatic neuroendocrine tumors (102).”
BackgroundKumar, R., Sharma, P., Singh, H., & Bal, C. S. (2014) · Indian Journal of Nuclear Medicine · doi:10.4103/0972-3919.125760 · Cited by 57
“These tumors can originate from endocrine glands such as the pituitary and adrenal medulla, as well as endocrine cell clusters in the thyroid or the pancreas and widely dispersed endocrine cells in the gastrointestinal and respiratory tract as well as skin.[2] As these tumors belong to the amine precursor uptake and d…”
BackgroundOutcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
Thomas, K. E. H., Voros, B. A., Taylor, M. M., Smeltzer, M. P., Griffin, R. P., Boudreaux, J. P., Thiagarajan, R., Woltering, E. A., & Ramirez, R. A. (2020) · Cancers · doi:10.3390/cancers12010206 · Cited by 56
Grozinsky‐Glasberg, S., Alexandraki, K., Angelousi, A. G., Chatzellis, E., Sougioultzis, S., & Kaltsas, G. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.04.013 · Cited by 60
Self-citation18F-FDOPA PET/CT imaging of insulinoma revisited
Imperiale, A., Sebag, F., Vix, M., Castinetti, F., Kessler, L., Moreau, F., Bachellier, P., Guillet, B., Namer, I.-J., Mundler, O., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2943-z · Cited by 55
Salvia, A. L., Modica, R., Rossi, R. E., Spada, F., Rinzivillo, M., Panzuto, F., Faggiano, A., Cinieri, S., & Fazio, N. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102560 · Cited by 57
Oh, S.-W., Prasad, V., Lee, D. S., & Baum, R. P. (2011) · International Journal of Molecular Imaging · doi:10.1155/2011/524130 · Cited by 57
Jahn, U., Ilan, E., Sandström, M., Lubberink, M., Garske‐Román, U., & Sundin, A. (2021) · Cancers · doi:10.3390/cancers13050962 · Cited by 59
“NENs are, as an entity, markedly heterogenous as a result of their differences in primary tumor sites, their degree of proliferation and functional status [5,6].”
BackgroundHernández, I., Espinosa-de-los-Monteros, A. L., Mendoza, V., Cheng, S., Molina, M., Sosa, E., & Mercado, M. (2006) · Archives of Medical Research · doi:10.1016/j.arcmed.2006.05.015 · Cited by 57
Raitila, A., Georgitsi, M., Karhu, A., Tuppurainen, K., Mäkinen, M. J., Birkenkamp‐Demtröder, K., Salmenkivi, K., Orntoft, T. F., Arola, J. T., Launonen, V., et al. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0025 · Cited by 55
Danti, G., Flammia, F., Matteuzzi, B., Cozzi, D., Berti, V., Grazzini, G., Pradella, S., Recchia, L., Brunese, L., & Miele, V. (2021) · La radiologia medica · doi:10.1007/s11547-021-01408-x · Cited by 57
Circulating markers for endocrine tumours of the gastroenteropancreatic tract
Ardill, J. E. S. (2008) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2008.008039 · Cited by 54
Sharma, P., Arora, S., Dhull, V. S., Naswa, N., Kumar, R., Ammini, A. C., & Bal, C. S. (2014) · Abdominal Imaging · doi:10.1007/s00261-014-0219-5 · Cited by 53
The treatment of hyperinsulinemic hypoglycaemia in adults: an update
On behalf of NIKE Group, Davi′, M. V., Pia, A., Guarnotta, V., Pizza, G., Colao, A., & Faggiano, A. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0536-3 · Cited by 51
“1 3 confusion, abnormal behaviour to epilepsy and coma; the second group comprises adrenergic symptoms such as palpitations, tremor, anxiety and cholinergic symptoms such as sweating, hunger and paresthesias [1, 2].”
BackgroundClinical syndromes related to gastrointestinal neuroendocrine neoplasms
Boutzios, G., & Kaltsas, G. (2015) · Frontiers of hormone research · doi:10.1159/000382053 · Cited by 50
Self-citationKocha, W., Maroun, J. A., Kennecke, H. F., Law, C. H. L., Metrakos, P. P., Ouellet, J. F., Reid, R. H., Rowsell, C. H., Shah, A., Singh, S., et al. (2010) · Current Oncology · doi:10.3747/co.v17i3.484 · Cited by 50
Murugesan, S. V., Varró, A., & Pritchard, D. M. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.03976.x · Cited by 49
Management of neuroendocrine tumors of unknown primary
Alexandraki, K., Angelousi, A. G., Boutzios, G., Kyriakopoulos, G., Rontogianni, D. P., & Kaltsas, G. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9437-9 · Cited by 48
Self-citationAllìa, E., Tarabra, E., Volante, M., Cerrato, M., Ghigo, E., Muccioli, G., & Papotti, M. G. (2005) · The Journal of Pathology · doi:10.1002/path.1839 · Cited by 48
“The presence of SRIF receptors (particularly subtype 2) correlates with the reported positivity of some parathyroid tumours on octreotide scintigraphy [28], although the absence of any biological effect of octreotide on parathormone secretion has been reported by others [29,30].”
BackgroundGastroenteropancreatic endocrine tumors
Weil, C. (1985) · Journal of Molecular Medicine · doi:10.1007/bf01731493 · Cited by 50
Faggiano, A., Mansueto, G., Ferollà, P., Milone, F., de del Caro, M. L. B., Lombardi, G., Colao, A. A. L., & Rosa, G. D. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345593 · Cited by 47
Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome: Review of Literature
Tonelli, F., Giudici, F., Fratini, G., & Brandi, M. L. (2011) · Endocrine Practice · doi:10.4158/ep10376.ra · Cited by 46
Sangster, G. P., Do, D., Previgliano, C., Li, B. C., LaFrance, D. R., & Heldmann, M. G. (2010) · HPB Surgery · doi:10.1155/2010/645728 · Cited by 45
GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers
Verbeek, W. H. M., Korse, C. M., & Tesselaar, M. E. T. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0971 · Cited by 47
Small bowel neuroendocrine tumors: From pathophysiology to clinical approach
Xavier, S. A., Rosa, B., & Cotter, J. (2016) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v7.i1.117 · Cited by 44
Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important
Jin, X., Spampatti, M. P., Spitzweg, C., & Auernhammer, C. J. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9443-6 · Cited by 45
Wu, Y., Pfeifer, A., Myschetzky, R., Garbyal, R. S., Rasmussen, P., Knigge, U., Bzorek, M., Kristensen, M., & Kjær, A. (2013) · Diagnostics · doi:10.3390/diagnostics3040344 · Cited by 45
“The historical median survival was around 2 years but with aggressive multimodal treatment by surgery, radiotherapy and peptide receptor therapy this has now been extended to 8 years [4].”
BackgroundTreatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review
Goglia, U., Ferone, D., Sidoti, M., Spaziante, R., Dadati, P., Ravetti, J.-L., Villa, G., Bodei, L., Paganelli, G., Minuto, F. M., et al. (2007) · Pituitary · doi:10.1007/s11102-007-0038-6 · Cited by 44
“b-emitters release electrons with sufficient energy to cause damage in the SSR positive cells and directly surrounding, via the so-called ‘‘cross-fire’’ effect, while sparing normal surrounding organs [27].”
BackgroundTumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome)
de Herder, W. W. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.05.007 · Cited by 44
Modlin, I. M., Moss, S. F., Gustafsson, B. I., Lawrence, B. J., Schimmack, S. J., & Kidd, M. S. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0794-7 · Cited by 48
“Insulinomas are the most common functioning tumors of the pancreas; patients present with hypoglycemia [35].”
BackgroundAnthony, L. B., & Vinik, A. I. (2011) · Pancreas · doi:10.1097/mpa.0b013e31821f66b4 · Cited by 43
“N euroendocrine tumors (NETs) are rare, slow-growing neoplasms originating from neuroendocrine cells in the digestive tract, pancreas, lungs, and liver.(1,2) Recent results from the Surveillance, Epidemiology and End Results (SEER) database, currently representative of 26% of the US population, showed that there has b…”
BackgroundCapdevila, J., Salazar, R., Halperín, I., Abad, A., & Yao, J. C. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9290-3 · Cited by 43
“become evident [8].”
Binderup, T., Knigge, U., Mogensen, A. M., Hansen, C. P., & Kjær, A. (2008) · Neuroendocrinology · doi:10.1159/000113128 · Cited by 44
“Most NE tumors are well differentiated and characterized as benign/low malignant (WHO 2000 classification group 1–2). However, 10–20p of the tumors show aggressive behavior with fast progression, fast development of metastases, and marked resistance to surgical and medical therapy (WHO 2000 classification group 3). Fo…”
BackgroundPreoperative localization of an insulinoma: selective arterial calcium stimulation test performance
Morera, J., Guillaume, A., Courtheoux, P., Palazzo, L., Rod, A., Joubert, M., & Reznik, Y. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0406-4 · Cited by 43
“1 3 40 % and 70–85 % for the two previous procedures [7, 8].”
BackgroundKay, R. G., Challis, B., Casey, R. T., Roberts, G. P., Meek, C. L., Reimann, F., & Gribble, F. M. (2018) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8183 · Cited by 45
“Pancreatic neuroendocrine tumours (PNETs) are rare neoplasms that account for 1–2% of all pancreatic tumours.(15) PNETs may be sporadic or part of an inherited tumour syndrome such as multiple endocrine neoplasia type 1 or von Hippel Lindau syndrome.”
BackgroundEbbers, S. C., Braat, A. J. A. T., Moelker, A. D., Stokkel, M. P. M., Lam, M. G. E. H., & Barentsz, M. W. (2020) · Trials · doi:10.1186/s13063-019-3888-0 · Cited by 43
Crosby, D. A., Donohoe, C. L., Fitzgerald, L. M., Muldoon, C., Hayes, B. D., O’Toole, D., & Reynolds, J. V. (2012) · Digestive Surgery · doi:10.1159/000342988 · Cited by 46
Ong, S. L., Garcea, G., Pollard, C., Furness, P. N., Steward, W. P., Rajesh, A., Spencer, L., Lloyd, D., Berry, D. P., & Dennison, A. R. (2009) · Pancreatology · doi:10.1159/000212085 · Cited by 45
Rubira, L., Deshayes, E., Santoro, L., Kotzki, P. O., & Fersing, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041051 · Cited by 43
“Neurological properties are based on the presence of dense granules similar to those found in serotonergic neurons that store monoamines [2]; endocrine properties refer to the synthesis and secretion of such mediators [3].”
BackgroundLudlam, W. H., & Anthony, L. B. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0062-9 · Cited by 41
Chau, I., Casciano, R., Willet, J., Wang, X., & Yao, J. C. (2013) · European Journal of Cancer Care · doi:10.1111/ecc.12085 · Cited by 40
“Given that neuroendocrine cells have the ability to secrete metabolically active substances, NET can cause a variety of distinct clinical syndromes, such as hyperinsulinaemia and carcinoid syndrome (Kaltsas et al. 2004).”
BackgroundSharma, P., Arora, S., Mukherjee, A., Pal, S., Sahni, P., Garg, P. K., Khadgawat, R., Thulkar, S. P., Bal, C. S., & Kumar, R. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000257 · Cited by 43
“Neuroendocrine tumors (NETs) are a heterogeneous group of tumors arising from neural crestYderived neuroendocrine cells.(1) These tumors can originate from endocrine glands such as the pituitary and adrenal medulla, as well as endocrine cell clusters in the thyroid or the pancreas and widely dispersed endocrine cells…”
BackgroundMultiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)
Effraimidis, G., Knigge, U., Rossing, M., Oturai, P., Rasmussen, Å. K., & Feldt‐Rasmussen, U. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.011 · Cited by 42
Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?
Perysinakis, I., Aggeli, C., Kaltsas, G., & Zografos, G. (2015) · HORMONES · doi:10.1007/bf03401399 · Cited by 39
Self-citationSunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma
Park, K.-S., Lee, J.-L., Ahn, H., Koh, J., Park, I., Choi, J. S., Kim, Y. R., Park, T. S., Ahn, J. H., Lee, D. H., et al. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp005 · Cited by 38
Surgical Management of Neuroendocrine Tumours of the Pancreas
Souche, F.-R., Hobeika, C., Hain, É., & Gaujoux, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092993 · Cited by 38
“clinical symptoms related to an hypersecretion f metabol cally active peptides [3,4].”
BackgroundPífano, M., Garona, J., Capobianco, C. S., González, N., Alonso, D. F., & Ripoll, G. V. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00011 · Cited by 38
“Successful treatment of disseminated NETs requires a multimodal approach where radical tumor surgery may be curative but is rarely possible (56).”
BackgroundNeuroendocrine Tumor Therapy with Lutetium-177: A Literature Review
Maqsood, M. H., Din, A. T. U., & Khan, A. H. A. (2019) · Cureus · doi:10.7759/cureus.3986 · Cited by 45
Neuroendocrine Tumors: a Relevant Clinical Update
Rizen, E. N., & Phan, A. T. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01217-z · Cited by 37
Bolanowski, M., Bednarczuk, T., Bobek‐Billewicz, B., Handkiewicz-Junak, D., Jeziorski, A., Nowakowska-Duława, E., Steinhof-Radwańska, K., Zajęcki, W., Zemczak, A., Kos‐Kudła, B., et al. (2014) · Endokrynologia Polska · doi:10.5603/ep.2013.0029 · Cited by 39
“The symptoms occur if serotonin and other biogenic amines are secreted directly to the systemic circulation; therefore, the carcinoid syndrome symptoms occur most often with hepatic metastases from NETs (approximately 95% of cases) [1,3].”
BackgroundBiological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas
Fazio, N., Cinieri, S., Lorizzo, K., Squadroni, M., Orlando, L., Spada, F., Maiello, E., Bodei, L., Paganelli, G., Fave, G. D., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70026-8 · Cited by 40
Nutritional and vitamin status in patients with neuroendocrine neoplasms
Clement, D. S. V. M., Tesselaar, M. E. T., van Leerdam, M. E., Srirajaskanthan, R., & Ramage, J. K. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i10.1171 · Cited by 37
Sequelae and survivorship in patients treated with 131I-MIBG therapy
Sze, W.-C., Grossman, A. B., Goddard, I., Amendra, D., Shieh, S. C. C., Plowman, P. N., Drake, W. M., Akker, S. A., & Druce, M. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.365 · Cited by 39
“Other treatment modalities have been discussed in detail in other publications (Kaltsas et al, 2004; Kwekkeboom et al, 2005; Basu et al, 2010; Druce et al, 2010).”
BackgroundSelf-citationDavì, M. V., Bodei, L., Francia, G., Bartolomei, M., Oliani, C., Scilanga, L., Reghellin, D., Falconi, M., Paganelli, G., Cascio, V. L., et al. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344149 · Cited by 36
Bongiovanni, A., Liverani, C., Foca, F., Fausti, V., Menna, G. D., Mercatali, L., Vita, A. D., Riva, N., Calpona, S., Miserocchi, G., et al. (2020) · Neuroendocrinology · doi:10.1159/000513218 · Cited by 35
Somatostatin Analogues: Treatment of Pituitary and Neuroendocrine Tumors
Colao, A., Faggiano, A., & Pivonello, R. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)82012-6 · Cited by 35
Neuroendocrine Carcinoma of the Colon and Rectum
Kim, D. H., Lee, W. Y., Yun, H. R., Choi, Y. C., Cho, Y. B., Yun, S. H., Kim, H. C., & Chun, H.-K. (2009) · Journal of the Korean Society of Coloproctology · doi:10.3393/jksc.2009.25.1.46 · Cited by 35
Çakır, M., Dworakowska, D., & Grossman, A. B. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01125_1.x · Cited by 35
“In patients with medullary thyroid carcinoma both SST analogues and tumour-targeted radioactive treatment using radiolabelled SST analogues have limited therapeutic value due to minor radioactivity uptake by these tumours in most patients [65].”
BackgroundSelf-citationRossi, R. E., Invernizzi, P., Mazzaferro, V., & Massironi, S. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640619890465 · Cited by 35
Neychev, V. K., Steinberg, S. M., Cottle‐Delisle, C., Merkel, R., Nilubol, N., Yao, J., Meltzer, P. S., Pacák, K., Marx, S. J., & Kebebew, E. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008248 · Cited by 34
The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours
Łapińska, G., Bryszewska, M. A., Fijołek-Warszewska, A., Kozłowicz-Gudzińska, I., Ochman, P., & Sackiewicz-Słaby, A. (2011) · Nuclear Medicine Review · doi:10.5603/nmr.2011.0004 · Cited by 34
Management of metastatic endocrine tumours
Plöckinger, U., & Wiedenmann, B. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.02.013 · Cited by 34
Öberg, K. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.01.001 · Cited by 33
“They maybe associated with a specific syndrome due to hormone hyper secretion, which differentiate ‘functioning’ from ‘non-functioning’ tumours, in which symptoms are related to the mass effect from tumour growth only [2].”
BackgroundSomatostatin analog octreotide LAR®in gastro–entero–pancreatic tumors
Öberg, K. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.26 · Cited by 33
New and Emerging Syndromes due to Neuroendocrine Tumors
Vinik, A. I., & Gonzales, M. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.12.010 · Cited by 34
Johnbeck, C. B., Knigge, U., Langer, S. W., Loft, A., Berthelsen, A. K., Federspiel, B., Binderup, T., & Kjær, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.174714 · Cited by 32
Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence
Dong, D.-H., Zhang, X., Lopez‐Aguiar, A. G., Poultsides, G. A., Makris, E. A., Rocha, F. G., Kanji, Z. S., Weber, S. M., Fisher, A. V., Fields, R. C., et al. (2019) · HPB · doi:10.1016/j.hpb.2019.05.020 · Cited by 32
Zografos, G. N., Stathopoulou, A., Mitropapas, G., Karoubalis, J., Kontogeorgos, G., Kaltsas, G., Piaditis, G. P., & Papastratis, G. (2005) · PubMed · Cited by 32
Self-citationCazzato, R. L., Garnon, J., Ramamurthy, N. K., Tsoumakidou, G., Impériale, A., Namer, I. J., Bachellier, P., Caudrelier, J. M., Rao, P. P., Koch, G., et al. (2016) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-016-1334-1 · Cited by 32
“Up to 18 % of small bowel tumours are symptomatic with abdominal pain, diarrhoea, and cutaneous flushing (‘‘carcinoid syndrome’’), usually secondary to liver metastases [2, 3].”
BackgroundDu, S., Wang, Z., Sang, X., Lu, X., Zheng, Y., Xu, H., Xu, Y., Chi, T., Zhao, H., Wang, W., et al. (2015) · Medicine · doi:10.1097/md.0000000000000388 · Cited by 32
on behalf of NIKE group, Guarnotta, V., Martini, C., Davì, M. V., Pizza, G., Colao, A. A. L., & Faggiano, A. (2017) · Endocrine · doi:10.1007/s12020-017-1420-4 · Cited by 33
“syndrome, due to ectopic ACTH secretion, can complicate the clinical course leading to a poorer prognosis [4].”
Cutaneous Vascular Disorders Associated with Internal Malignancy
Tal, A. K. E., & Tannous, Z. S. (2007) · Dermatologic Clinics · doi:10.1016/j.det.2007.08.001 · Cited by 33
Gastroenteropancreatic endocrine tumors
Meeker, A. K., & Heaphy, C. M. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.015 · Cited by 34
“…prognostic information, with locally advanced and metastatic disease portending a poor prognosis, as complete surgical resection – currently the only reliable curative treatment – is impossible in such cases (Yao et al.,2008a; Modlin et al., 2008; Kaltsas et al., 2004a; Metz and Jensen, 2008).”
BackgroundLiu, S., Rao, D. D., Nemunaitis, J. J., Senzer, N. N., Zhou, G., Dawson, D. W., Gingras, M., Wang, Z., Gibbs, R. A., Norman, M. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040452 · Cited by 31
“This is important since there are no current effective medical treatments for the devastating hormonal symptoms associated with pancreatic neuroendocrine tumors and nesidioblastosis [38].”
BackgroundCella, D. F., Beaumont, J. L., Hudgens, S. A., Marteau, F., Feuilly, M., Houchard, A., Lapuerta, P., Ramage, J. K., Pavel, M. E., Hörsch, D., et al. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.008 · Cited by 33
Eckert‐Norton, M., & Kirk, S. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-v98i10-39a · Cited by 32
Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms
Kaltsas, G., Grozinsky‐Glasberg, S., Alexandraki, K., Thomas, D., Tsolakis, A. V., Gross, D., & Grossman, A. B. (2014) · Clinical Endocrinology · doi:10.1111/cen.12476 · Cited by 32
Self-citationElicitation of health state utilities in neuroendocrine tumours
Swinburn, P., Wang, J. Y., Chandiwana, D., Mansoor, W., & Lloyd, A. J. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.670175 · Cited by 31
“Once complete the participants undertook the TTO exercise(17), which involved the following for each health state: participants were required to choose whether they preferred: (1) to live in the health state for a period of 10 years followed by death; (2) to live in the health state for 10-x years in full health; or (…”
Michael, M., García‐Carbonero, R., Weber, M. M., Lombard‐Bohas, C., Toumpanakis, C., & Hicks, R. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0305 · Cited by 32
Rust, E., Hubelé, F., Marzano, E., Goichot, B., Pessaux, P., Kurtz, J., & Impériale, A. (2012) · Cancer Imaging · doi:10.1102/1470-7330.2012.0026 · Cited by 31
“[4] Kaltsas GA, Besser GM, Grossman AB.”
BackgroundThe present and future role of (111)In pentetreotide in the PET era.
Rambaldi, P. F., Cuccurullo, V., Briganti, V., & Mansi, L. (2005) · PubMed · Cited by 31
Chuang, C.-C., Bhurke, S., Chen, S.-Y., Brulais, S., & Gabriel, S. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.975233 · Cited by 30
“Each individual with a NET was categorized into two mutually exclusive cohorts based on whether they received: (1) medical therapy only (medical therapy cohort); or (2) tumor resection surgery (see the Appendix) with/without medical therapy (surgical therapy cohort) during the entire 12-month post-index period.”
MethodMidgut Neuroendocrine Tumors: Imaging Assessment for Surgical Resection
Woodbridge, L., Murtagh, B., Yu, D., & Planche, K. (2014) · Radiographics · doi:10.1148/rg.342135504 · Cited by 30
“It utilizes 111In DTPA octreotide because octreotide is a long-acting somatostatin analog and binds to the SSTRs expressed by MNETs (3,11).”
BackgroundMethodInfluentialSurgical management of pancreatic neuroendocrine tumors: an introduction
Hain, É., Sindayigaya, R., Fawaz, J., Gharios, J., Bouteloup, G., Soyer, P. A., Bertherat, J. Y., Prat, F., Terris, B., Coriat, R., et al. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1703677 · Cited by 30
Esfahani, S. A., Ferreira, C. D. A., Summer, P., Mahmood, U., & Heidari, P. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265391 · Cited by 30
“Although the main focus is to stabilize the disease and manage symptoms (4), this focus also improves the median overall survival from approximately 2 to 8 y after initial diagnosis (7).”
BackgroundChaicham, A., Sahasithiwat, S., Tuntulani, T., & Tomapatanaget, B. (2013) · Chemical Communications · doi:10.1039/c3cc45077e · Cited by 30
Colleran, J. J., & Breslin, C. B. (2011) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2011.12.020 · Cited by 30
Unusual Complication of a Pancreatic Neuroendocrine Tumor Presenting with Malignant Hypercalcemia
Kanakis, G., Kaltsas, G., Granberg, D. O., Grimelius, L., Papaioannou, D., Tsolakis, A. V., & Öberg, K. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2592 · Cited by 30
Self-citationPrognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors
Song, K. B., Kim, S. C., Kim, J. H., Seo, D. W., Hong, S., Park, K., Hwang, D. W., Lee, J. H., & Lee, Y. J. (2015) · Pancreas · doi:10.1097/mpa.0000000000000493 · Cited by 30
The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers
Volante, M., Righi, L., Berruti, A., Rindi, G., & Papotti, M. G. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1060-7 · Cited by 29
Alexandraki, K., Karapanagioti, A., Karoumpalis, I., Boutzios, G., & Kaltsas, G. (2017) · BioMed Research International · doi:10.1155/2017/9856140 · Cited by 30
“Another feature of GEP-NENs is that some may occur in the context of familial syndromes [2, 17, 18].”
BackgroundInfluentialSelf-citationDiakatou, E., Kaltsas, G., Tzivras, M., Kanakis, G., Papaliodi, E., & Kontogeorgos, G. (2011) · Endocrine Pathology · doi:10.1007/s12022-011-9149-8 · Cited by 29
Self-citationManagement of the hormonal syndrome of neuroendocrine tumors
Gut, P., Waligórska‐Stachura, J., Czarnywojtek, A., Sawicka‐Gutaj, N., Bączyk, M., Ziemnicka, K., Fischbach, J., Woliński, K., Kaznowski, J., Wrotkowska, E., et al. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.60311 · Cited by 29
Metadata
- Authors
- Kaltsas, G. A., Besser, G. M., & Grossman, A. B.
- Affiliations
- St Bartholomew's Hospital (GB)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2004-06-01
- Volume
- 25
- Issue
- 3
- Pages
- 458-511
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2031301095
- Semantic Scholar
- b09a37699a89446c4662f1bc87eb975bf31118b7
- Cited by
- 674
- References
- 670
- Citations by year
- 2026: 4 · 2025: 19 · 2024: 17 · 2023: 26 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 24 · 2018: 31 · 2017: 27 · 2016: 34 · 2015: 46 · 2014: 30 · 2013: 37 · 2012: 49
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- neuroendocrine tumors, diagnosis, tumor markers, endocrine syndromes, somatostatin analogues, MIBG scintigraphy, endoscopic ultrasound, interferon-alpha, chemotherapy, radionuclide therapy, multimodal therapy, quality of life
- MeSH terms
- Adrenal Gland Neoplasms, Animals, Antineoplastic Combined Chemotherapy Protocols, Gastrointestinal Neoplasms, Humans, Pancreatic Neoplasms, Parathyroid Neoplasms, Pituitary Neoplasms, Prognosis, Quality of Life, Sensitivity and Specificity, Somatostatin, Thyroid Neoplasms, Tomography, X-Ray Computed, Biomarkers, Tumor, Interferon-alpha, Carcinoma, Neuroendocrine, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.